Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
Frontiers in Immunology|July 2, 2019
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMTAntonio M Risitano, Serena Marotta, Patrizia Ricci, et al.The Science of the Total Environment|May 3, 2023
Environmental quality improvement of a mariculture plant after its conversion into a multi-trophic systemLoredana Stabili, Adriana Giangrande, Daniele Arduini, et al.Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|May 7, 2020
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasisAdriana Carino, Michele Biagioli, Silvia Marchianò, et al.Biology|April 23, 2022
An Integrated Monitoring Approach to the Evaluation of the Environmental Impact of an Inshore Mariculture Plant (Mar Grande of Taranto, Ionian Sea)Adriana Giangrande, Margherita Licciano, Daniele Arduini, et al.Nutrients|August 10, 2019
The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic DysfunctionsMichele Biagioli, Adriana Carino, Chiara Fiorucci, et al.Haematologica|September 17, 2013
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuriaTommaso Rondelli, Antonio M Risitano, Régis Peffault de Latour, et al.Frontiers in Oncology|March 31, 2023
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinomaCristina Di Giorgio, Rachele Bellini, Antonio Lupia, et al.Blood|February 6, 2014
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuriaAntonio M Risitano, Daniel Ricklin, Yijun Huang, et al.Blood|January 31, 2009
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumabAntonio M Risitano, Rosario Notaro, Ludovica Marando, et al.Journal of the American Heart Association|November 24, 2023
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver DiseaseSilvia Marchianò, Michele Biagioli, Martina Bordoni, et al.Pageof 5